Harmonizing Surveillance Methodologies for Group A Streptococcal Diseases

Group A Streptococcus (Strep A) is responsible for a significant global health and economic burden. The recent prioritization of Strep A vaccine development by the World Health Organization has prompted global research activities and collaborations. To progress this prioritization, establishment of robust surveillance for Strep A to generate updated regional disease burden estimates and to establish platforms for future impact evaluation is essential. Through the activities of the Strep A Vaccine Global Consortium (SAVAC), we have refined and harmonized surveillance protocols for 7 Strep A disease endpoints with a view that these will form part of surveillance standards for ongoing research and public health activities.

Automated summary

Group A Streptococcus (Strep A) is a significant global health and economic burden, and the World Health Organization's prioritization of Strep A vaccine development has led to increased research and collaboration. Robust surveillance is essential for generating accurate disease burden estimates and evaluating the impact of future interventions.